Central nervous system damage markers in children: current state of the problem

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


Pathology of the central nervous system (CNS) occupies one of the leading places in the structure of childhood morbidity and mortality. In the modern world the diagnosis of central nervous system diseases is based not only on the a thorough history, identification of certain neurological symptoms during an objective medical examination of the child and data from various neuroimaging methods, but also on the use of laboratory research methods with the identification of specific markers which indicate a pathological process occurring in the tissues of the brain and spinal cord. The article presents modern data on the biochemical parameters indicating damage to the nervous tissue, as well as their role in conditions of homeostasis and the prospects for further research. We analyzed the latest domestic and foreign literature on the properties and role of such indicators as neurotrophic growth factor, vascular endothelial growth factor, monocytic chemotactic protein, trigger receptor expressed on myeloid cells-1, trigger receptor expressed on myeloid cells-2, transforming growth factor, fractalkin, a nerve growth factor, which is a promising direction in the study of damage to nerve tissue. We can conclude that а study of the level of these markers will help diagnose the presence of damage to the nerve tissue, its severity, and therefore, select the right individual therapy for each specific child, thereby preventing the development of severe neurological consequences.


Full Text

Restricted Access

About the authors

Marina S. Panova

Chita State Medical Academy, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: merik2002@mail.ru

Russian Federation, Chita

Assistant Professor, Department of Propaedeutics of Children’s Diseases

Aleksandra S. Panchenko

Chita State Medical Academy, Ministry of Healthcare of the Russian Federation

Email: sashawomen18@mail.ru

Russian Federation, Chita

MD, PhD, Dr Med Sci, Associate Professor, Head, Department of Propaedeutics of Children’s Diseases

References

  1. Белоусова Н.П., Громова О.А., Пепеляев Е.Г., и др. Взаимосвязь когнитивных нарушений и уровня BDNF у лиц молодого возраста // Медицина в Кузбассе. – 2017. – Т. 16. – № 4. – С. 39–43. [Belousova NP, Gromova OA, Pepelyaev EG, et al. Meditsina v Kuzbasse. 2017;16(4):39-43. (In Russ.)]
  2. Воронина Л.П., Шварц Ю.Г., Якушев Р.Б., Полунина Е.А. Анализ уровня трансформирующего фактора роста β1 при хронической сердечной недостаточности // Астраханский медицинский журнал. – 2018. – Т. 13. – № 3. – С. 9–15. [Voronina LP, Shvarts YuG, Yakushev RB, Polunina EA. Analysis of the level of transforming growth factor β1 in chronic heart failure. Astrakhan medical journal. 2018;13(3):9-15. (In Russ.)] https://doi.org/10.17021/2018.13.3.9.15.
  3. Голубова Т.Ф., Цукурова Л.А., Нуволи А.В., Власенко С.В. Оценка состояния опиоидной системы у детей с аутизмом и динамика ее показателей в процессе дельфинотерапии // Вестник физиотерапии и курортологии. – 2017. – Т. 23. – № 4. – С. 83–87. [Golubova TF, Tsukurova LA, Nuvoli AV, Vlasenko SV. Otsenka sostoyaniya opioidnoy sistemy u detey s autizmom i dinamika ee pokazateley v protsesse del’finoterapii. Vestnik fizioterapii i kurortologii. 2017;23(4):83-87. (In Russ.)]
  4. Дочкина Е.С., Устинова А.В., Таранушенко Т.Е. Анализ перинатального периода и поражений ЦНС у детей с ДЦП // Сибирское медицинское обозрение. – 2018. – № 5. – С. 41–47. [Dochkina ES, Ustinova AV, Taranushenko TE. Analysis of perinatal period and damage of CNS in children with CP. Siberian medical review. 2018;(5):41-47. (In Russ.)] https://doi.org/10.20333/2500136-2018-5-41-47.
  5. Коробцов А.В., Калиниченко С.Г., Матвеева Н.Ю. Характеристика нейротрофинов и их локализация в неокортексе крыс при острой экспериментальной ишемии // Вестник новых медицинских технологий. Электронное издание. – 2018. – № 4. – С. 235–241. [Korobtsov AV, Kalinichenko SG, Matveeva NYu. Characterization of neurotrophins and their localization in the neocortex of rats with acute experimental ischemia. Journal of new medical technologies. 2018;(4): 235-241. (In Russ.) https://doi.org/10.24411/2075-4094-2018-16130.
  6. Колотов К.А., Распутин П.Г. Моноцитарный хемотаксический протеин-1 в физиологии и медицине // Пермский медицинский журнал. – 2018. – Т. 35. – № 3. – С. 99–105. [Kolotov KA, Rasputin PG. Monocytic chemotactic protein-1 in physiology and medicine (review of literature). Perm medical journal. 2018;35(3):99-105. (In Russ.)] https://doi.org/10.17816/pmj35399-105.
  7. Красноруцкая О.Н., Балакирева Е.А., Бугримов Д.Ю., и др. Роль фактора роста нервов в оценке степени тяжести клинических проявлений и исходов перинатального поражения ЦНС у детей первого года жизни // Смоленский медицинский альманах. – 2016. – № 3. – С. 83–88. [Krasnorutskiy ON, Balakirev EA, Bugrimov DYu, et al. Role of nerve growth factor in assessing the degree of severity of clinical manifestations and outcome of perinatal lesions of the CNS in infants. Smolenskiy meditsinskiy al’manakh. 2016;(3):83-88. (In Russ.)]
  8. Ордиянц И.М., Барабашева С.С. Неразвивающаяся беременность: взгляд на проблему // Акушерство и гинекология: новости, мнения, обучение. – 2018. – № 3. – С. 92–96. [Ordiyants IM, Barabasheva SS. Non-developing pregnancy: view of the problem. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2018;(3):92-96. (In Russ.)]. https://doi.org/10.24411/2303-9698-2018-13010.
  9. Острова И.В., Голубева Н.В., Кузовлев А.Н., Голубев А.М. Прогностическая значимость и терапевтический потенциал мозгового нейротрофического фактора BDNF при повреждении головного мозга (обзор) // Общая реаниматология. – 2019. – Т. 15. – № 1. – С. 70–86. [Ostrova IV, Golubeva NV, Kuzovlev AN, Golubev AM. Prognostic Value and Therapeutic Potential of Brain-Derived Neurotrophic Factor (BDNF) in Brain Injuries (Review). General Reanimatology. 2019;15(1): 70-86. (In Russ.)] https://doi.org/10.15360/1813-9779-2019-1-70-86.
  10. Пекельдина Е.С., Николаев С.В., Антипова Т.А., Крыжановский С.А. Изучение ангиотропной активности фактора роста нервов в опытах на культуре эндотелиальных клеток человека // Фармакокинетика и фармакодинамика. – 2018. – № 1. – С. 32–35. [Pekeldina ES, Nicolaev SV, Antipova TA, Kryzhanovskii SA. Study of angiotropic activity of the nerve growth factor in experiments on human endothelial cell culture (HUVEC). Farmakokinetika i farmakodinamika. 2018;(1): 32-35. (In Russ.)]. https://doi.org/10.24411/2587-7836-2018-10004.
  11. Петренкова Н.С., Сергеева В.А., Пахомов Д.А. Гемодинамические паттерны у новорожденных с гипоксически-ишемической энцефалопатией при проведении терапевтической гипотермии // Забайкальский медицинский вестник. – 2017. – № 2. – С. 72–77. [Petrenkova NS, Sergeeva VA, Pachomov DA. Hemodynamic patterns in neonates with hypoxic-ischemic encephalopathy during theraputic hypothermia. Zabaykal’skiy meditsinskiy vestnik. 2017;(2):72-77. (In Russ.)]
  12. Пономаренко Ю.Н. Нейротрофины в санаторно-курортной реабилитации детей с детским церебральным параличом // Вестник физиотерапии и курортологии. – 2019. – № 1. – С. 78–83. [Ponomarenko YuN. Neurotrophins in sanatorium-resort rehabilitation of children with cerebral palsy. Vestnik fizioterapii i kurortologii. 2019;(1):78-83. (In Russ.)]
  13. Терехов И.В., Гук О.В., Бондарь С.С. Факторный анализ экспрессии паттерн-распознающих рецепторов и терминальных протеинкиназ MAPK/SAPK сигнального пути у реконвалесцентов внебольничной пневмонии // Вестник новых медицинских технологий. – 2017. – Т. 24. – № 3. – С. 156–162. [Terekhov IV, Guk OV, Bondar SS. Journal of new medical technologies. 2017;24(3):156-162. (In Russ.)] https://doi.org/10.12737/article_59c4a947f0e875.20026380.
  14. Цукурова Л.А., Власенко С.В., Нуволин А.В. Оценка нейропротективных свойств серотонинергической модулирующей системы мозга у детей с расстройствами аутистического спектра // Таврический журнал психиатрии. – 2016. – Т. 20. – № 4. – С. 30–37. [Tsukurova LA, Vlasenko SV, Nuvoli AV. Assessment of neuroprotective properties of the serotonergic modulating brain system in children with disorders of the autism spectrum. Tavricheskiy zhurnal psikhiatrii. 2016;20(4):30-37. (In Russ.)]
  15. Шевченко В.Е., Ковалев С.В., Арноцкая Н.Е., и др. Молекулярные детерминанты действия трансформирующего фактора роста бета-1 на клетки глиобластомы человека // Успехи молекулярной онкологии. – 2016. – Т. 3. – № 2. – С. 50–59. [Shevchenko VE, Kovalev SV, Arnotskaya NE, et al. Molecular determinants of transforming growth factor beta-1 action on human glioblastoma cells. Advances in molecular oncology. 2016;3(2):50-59. (In Russ.)]. https://doi.org/10.17650/2313-805X-2016-3-2-50-59.
  16. Al-Ayadhi L, Alhowikan AM, Halepoto DM. Impact of Auditory Integrative Training on Transforming Growth Factor-beta1 and Its Effect on Behavioral and Social Emotions in Children with Autism Spectrum Disorder. Med Princ Pract. 2018;27(1):23-29. https://doi.org/10.1159/000486572.
  17. Amano I, Takatsuru Y, Toya S, et al. Aberrant Cerebellar Development in Mice Lacking Dual Oxidase Maturation Factors. Thyroid. 2016;26(5):741-752. https://doi.org/10.1089/thy.2015.0034.
  18. Araujo AP, Diniz LP, Eller CM, et al. Effects of Transforming Growth Factor Beta 1 in Cerebellar Development: Role in Synapse Formation. Front Cell Neurosci. 2016;10:104. https://doi.org/10.3389/fncel.2016.00104.
  19. Baba N, Wang F, Iizuka M, et al. Induction of regional chemokine expression in response to human umbilical cord blood cell infusion in the neonatal mouse ischemia-reperfusion brain injury model. PLoS One. 2019;14(9): e0221111. https://doi.org/10.1371/journal.pone.0221111.
  20. Bajnok A, Berta L, Orban C, et al. Cytokine production pattern of T lymphocytes in neonatal arterial ischemic stroke during the first month of life-a case study. J Neuroinflammation. 2018;15(1):191. https://doi.org/10.1186/s12974-018-1229-y.
  21. Cardenas-Rivera A, Campero-Romero AN, Heras-Romero Y, et al. Early Post-stroke Activation of Vascular Endothelial Growth Factor Receptor 2 Hinders the Receptor 1-Dependent Neuroprotection Afforded by the Endogenous Ligand. Front Cell Neurosci. 2019;13:270. https://doi.org/10.3389/fncel.2019.00270.
  22. Cosky EEP, Ding Y. The role of vascular endothelial growth factor in angiogenesis and brain circulation after stroke. Brain Circ. 2018;4(2):73-75. https://doi.org/10.4103/bc.bc_8_18.
  23. Ganta VC, Choi M, Farber CR, Annex BH. Antiangiogenic VEGF165b Regulates Macrophage Polarization via S100A8/S100A9 in Peripheral Artery Disease. Circulation. 2019;139(2):226-242. https://doi.org/10.1161/CIRCULATIONAHA.118.034165.
  24. Guiraut C, Cauchon N, Lepage M, Sebire G. Perinatal Arterial Ischemic Stroke Is Associated to Materno-Fetal Immune Activation and Intracranial Arteritis. Int J Mol Sci. 2016;17(12). https://doi.org/10.3390/ijms17121980.
  25. Gervois P, Lambrichts I. The Emerging Role of Triggering Receptor Expressed on Myeloid Cells-2 as a Target for Immunomodulation in Ischemic Stroke. Front Immunol. 2019;10:1668. https://doi.org/10.3389/fimmu.2019.01668.
  26. Guo H, Zhou H, Lu J, et al. Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury. Neural Regen Res. 2016;11(1):174-179. https://doi.org/10.4103/1673-5374.175067.
  27. Kurisu K, Zheng Z, Kim JY, et al. Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental stroke. J Cereb Blood Flow Metab. 2019;39(10):1906-1918. https://doi.org/10.1177/0271678X18817282.
  28. Lauro C, Chece G, Monaco L, et al. Fractalkine Modulates Microglia Metabolism in Brain Ischemia. Front Cell Neurosci. 2019;13:414. https://doi.org/10.3389/fncel.2019.00414.
  29. Melton DW, McManus LM, Gelfond JA, Shireman PK. Temporal phenotypic features distinguish polarized macrophages in vitro. Autoimmunity. 2015;48(3):161-176. https://doi.org/10.3109/08916934.2015.1027816.
  30. Richard SA, Sackey M, Su Z, Xu H. Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke. Biosci Rep. 2017;37(6). https://doi.org/10.1042/BSR20171104.
  31. Sanchez-Infantes D, Cereijo R, Sebastiani G, et al. Nerve Growth Factor Levels in Term Human Infants: Relationship to Prenatal Growth and Early Postnatal Feeding. Int J Endocrinol. 2018;2018:7562702. https://doi.org/10.1155/2018/7562702.
  32. Schenck K, Schreurs O, Hayashi K, Helgeland K. The Role of Nerve Growth Factor (NGF) and Its Precursor Forms in Oral Wound Healing. Int J Mol Sci. 2017;18(2). https://doi.org/10.3390/ijms18020386.
  33. van Schie PE, Schijns J, Becher JG, et al. Long-term motor and behavioral outcome after perinatal hypoxic-ischemic encephalopathy. Eur J Paediatr Neurol. 2015;19(3):354-359. https://doi.org/10.1016/j.ejpn.2015.01.005.
  34. Sprincean M, Hadjiu, Calcii C, et al. Vascular endothelial growth factor: an important biomarker in pediatric ischemic stroke. Biological Markers in Fundamental and Clinical Medicine. 2019;3(1):76-77. https://doi.org/10.29256/v.03.01.2019.escbm49.
  35. Ulland TK, Song WM, Huang SC, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease. Cell. 2017;170(4):649-663 e613. https://doi.org/10.1016/j.cell.2017.07.023.
  36. Weehuizen TA, Hommes TJ, Lankelma JM, et al. Triggering Receptor Expressed on Myeloid Cells (TREM)-2 Impairs Host Defense in Experimental Melioidosis. PLoS Negl Trop Dis. 2016;10(6):e0004747. https://doi.org/10.1371/journal.pntd.0004747.
  37. Wu R, Li X, Xu P, et al. TREM2 protects against cerebral ischemia/reperfusion injury. Mol Brain. 2017;10(1):20. https://doi.org/10.1186/s13041-017-0296-9.
  38. Wu Q, Zhou W, Yin S, et al. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer. Hepatology. 2019;70(1):198-214. https://doi.org/10.1002/hep.30593.
  39. Xu P, Zhang X, Liu Q , et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell Death Dis. 2019;10(8):555. https://doi.org/10.1038/s41419-019-1777-9.
  40. Yu FPS, Dworski S, Medin JA. Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency. Sci Rep. 2018;8(1):1808. https://doi.org/10.1038/s41598-018-20052-6.
  41. Zhang HT, Zhang P, Gao Y, et al. Early VEGF inhibition attenuates blood-brain barrier disruption in ischemic rat brains by regulating the expression of MMPs. Mol Med Rep. 2017;15(1):57-64. https://doi.org/10.3892/mmr.2016.5974.
  42. Zhao YC, Hu T, Chen Y, Du KT. Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome. Balkan Med J. 2019;36(6):331-336. https://doi.org/10.4274/balkanmedj.galenos.2019.2019.6.47.
  43. Zhou X, Wang Y, Wang Y, et al. Inhibition of triggering receptor expressed on myeloid cells-1 ameliorates experimental autoimmune neuritis. Mol Med Rep. 2017;15(4):1565-1570. https://doi.org/10.3892/mmr. 2017.6167.

Statistics

Views

Abstract - 99

PDF (Russian) - 0

PDF (English) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Panova M.S., Panchenko A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies